絞り込み

16535

広告

Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies.

著者 van Schie KA , Kruithof S , Ooijevaar-de Heer P , Derksen NIL , van de Bovenkamp FS , Saris A , Vidarsson G , Bentlage AEH , Jiskoot W , Romeijn S , Koning RI , Bos E , Stork EM , Koeleman CAM , Wuhrer M , Wolbink G , Rispens T
Ann Rheum Dis.2018 Jun 26 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (11view , 0users)

Full Text Sources

Therapeutic antibodies can provoke an antidrug antibody (ADA) response, which can form soluble immune complexes with the drug in potentially high amounts. Nevertheless, ADA-associated adverse events are usually rare, although with notable exceptions including infliximab. The immune activating effects and the eventual fate of these 'anti-idiotype' complexes are poorly studied, hampering assessment of ADA-associated risk of adverse events. We investigated the in vitro formation and biological activities of ADA-drug anti-idiotype immune complexes using patient-derived monoclonal anti-infliximab antibodies.
PMID: 29945923 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード